2 weeks Ago By ABMN Staff
AbbVie Inc. ( NYSE:ABBV – Free Report ) – Leerink Partnrs boosted their FY2024 EPS estimates for shares of AbbVie in a report released on Wednesday, October 30th. Leerink Partnrs analyst D.
Risinger now expects that the company will post earnings of $10.94 per share for the year, up from their prior forecast of $10.84.
The consensus estimate for AbbVie’s current full-year earnings is $10.97 per share. AbbVie ( NYSE:ABBV – Get Free Report ) last released its quarterly earnings results on Wednesday, October 30th.
The company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.92 by $0.
08. The business had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.
28 billion. AbbVie had a net margin of 9.22% and a return on equity of 226.
99%. The firm’s revenue was up 3.8% compared to the same quarter last year.
During the same quarter in the previous year, the business earned $2.95 earnings per share. Check Out Our Latest Analysis on ABBV AbbVie Stock Up 0.
6 % ABBV opened at $201.69 on Monday. The company has a market capitalization of $356.
25 billion, a PE ratio of 70.03, a price-to-earnings-growth ratio of 2.54 and a beta of 0.
63. The business has a 50-day moving average of $194.29 and a 200-day moving average of $180.
10. The company has a debt-to-equity ratio of 8.51, a current ratio of 0.
81 and a quick ratio of 0.71. AbbVie has a fifty-two week low of $135.
85 and a fifty-two week high of $207.32. Institutional Trading of AbbVie A number of large investors have recently added to or reduced their stakes in ABBV.
Fairway Wealth LLC acquired a new position in AbbVie in the 2nd quarter valued at about $26,000. Ridgewood Investments LLC bought a new position in AbbVie during the 2nd quarter worth $27,000. Quest Partners LLC lifted its holdings in shares of AbbVie by 4,140.
0% during the second quarter. Quest Partners LLC now owns 212 shares of the company’s stock worth $36,000 after buying an additional 207 shares in the last quarter. Marquette Asset Management LLC acquired a new position in shares of AbbVie in the third quarter valued at about $39,000.
Finally, Burkett Financial Services LLC raised its stake in AbbVie by 61.2% in the 3rd quarter. Burkett Financial Services LLC now owns 216 shares of the company’s stock worth $43,000 after purchasing an additional 82 shares in the last quarter.
Institutional investors and hedge funds own 70.23% of the company’s stock. AbbVie Increases Dividend The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th.
Shareholders of record on Wednesday, January 15th will be given a dividend of $1.64 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.
55. The ex-dividend date is Wednesday, January 15th. This represents a $6.
56 annualized dividend and a dividend yield of 3.25%. AbbVie’s payout ratio is 215.
28%. About AbbVie ( Get Free Report ) AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Further Reading Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter ..
